NYRADA INC (ASX:NYR) 8 These cardioprotective effects were accompanied by improved cardiac structure and function, reduced biomarkers of injury, and a marked decrease in the occurrence of life-threatening arrhythmias such as ventricular fibrillation and tachycardia. Taken together, these results reinforce the potential for Xolatryp to provide a meaningful treatment for AMI, especially in clinical scenarios such as percutaneous coronary intervention (PCI), where reperfusion injury is a known and unavoidable challenge. Xolatryp also demonstrated significant neuroprotective effects in a preclinical study conducted in collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney. In this study, which simulated penetrating traumatic brain injury commonly sustained by military personnel, Xolatryp showed statistically significant reductions in lesion volume, preserved mitochondrial integrity, and minimized neuroinflammation. These findings were validated using blinded, high-resolution MRI analysis and represent an important milestone in our ongoing evaluation of the drug's broader applications in both military and civilian trauma. To better align with our long-term clinical and commercial objectives, the Company formally rebranded NYR-BI03 under the name Xolatryp. A provisional patent was filed to protect the drug’s chemical structure, and a subsequent international patent search confirmed the compound’s novelty and inventiveness. This development strengthens our intellectual property portfolio and positions Nyrada as a leader in TRPCtargeted therapeutic development. Throughout the financial year, Nyrada maintained strong financial discipline while ensuring sufficient funding for clinical and research programs. In October 2024, the Company successfully raised AU$3.45 million (before costs) via a fully subscribed placement and Securities Purchase Plan. Additional participation from NonExecutive Directors was secured following approval at the Extraordinary General Meeting held in April 2025. Government support also contributed meaningfully, with AU$1.24 million received in December 2024 under the Commonwealth Government’s R&D Tax Incentive scheme. As in prior years, Nyrada will lodge a similar claim for FY2025 for an estimated rebate of AU$2.1 million. As at 30 June 2025, Nyrada’s cash balance stood at AU$2.93 million. Following the end of the financial year, the Company further strengthened its balance sheet through another placement, raising AU$8.25 million (before costs). With this new capital, Nyrada is fully funded to undertake its Phase IIa trial, drug manufacturing, and research into new indications. As we move into FY2026, the Company is buoyed by strong clinical momentum and compelling scientific validation. With the Phase I trial complete and additional therapeutic indications under active evaluation, our strategic focus is now on the planning and execution of a Phase IIa clinical trial. The road ahead is clear, and the groundwork laid over the past year places us in a strong position to deliver on our clinical objectives and generate further value for shareholders. In closing, I would like to extend my heartfelt thanks to our exceptional team of scientists, clinical partners, and advisors whose dedication has propelled Nyrada forward. We have achieved much, but we are only just beginning. With conviction and clarity, we look forward to FY2026 as a defining chapter in our mission to bring transformative therapies to patients in need. Sincerely, James Bonnar Chief Executive Officer Nyrada Inc.
RkJQdWJsaXNoZXIy MjE2NDg3